Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
March 08 2022 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, will release financial results for
the quarter and year ended December 31, 2021 after the market close
on Tuesday, March 22, 2022. Ron Rocca, Exagen’s President and Chief
Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark
Hazeltine, Chief Operating Officer, will host a conference call to
review the Company’s results at 4:30 PM ET (1:30 PM PT).
Interested parties may access the conference call by dialing
(877) 407-3982 (U.S.) or (201) 493-6780 (international).
Participants wishing to access the call via webcast should use the
link posted on the Exagen investor relations website at
investors.exagen.com.
A replay of the conference call will be available until Tuesday,
March 29, 2022 at 11:59 PM ET (8:59 PM PT). Interested parties may
access the replay of the conference call by dialing (844) 512-2921
(U.S.) or (412) 317-6671 (international) using passcode 13727619.
Additionally, a recording of the webcast will be available using
the link on the Exagen investor relations website approximately 30
minutes after the call concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
CONTACTS:
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024